Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）

Inclusion Criteria: * IPF diagnosed, according to 2018 American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic Association (ALAT) IPF guideline for diagnosis and management; * Dlco (corrected for Hb): 30%-79% predicted of normal; * FVC\>= 50% predicted of normal; Exclusion Criteria: * FEV1/FVC\< 0.7; * PaO2 in resting state without oxygen inhalation \< 50mmHg; * Subjects who were likely to be lung transplant recipients or expected to survive less than 1 year during the study period as assessed by the investigator; * Poorly controlled cardiovascular and cerebrovascular diseases; * Patients who had used nidanib, pirfenidone, interferon, n-acetylcysteine, azathioprine, cyclophosphamide, cyclosporine, prednisone \> 15mg/ day (or equivalent dose of other glucocorticoids) within 4 weeks before enrollment; Those who had used Chinese herbal medicine or acupuncture treatment within 1 week before enrollment;